24534-93-8

Usage

Uses

Used in Pharmaceutical Industry:
3-HYDROXYBUTANOHYDRAZIDE is used as an antitubercular agent for its strong effect on the bacteria that causes tuberculosis. It is an essential part of treatment regimens designed to combat the disease.
Used in Tuberculosis Treatment:
3-HYDROXYBUTANOHYDRAZIDE is used as a medication to inhibit the growth of Mycobacterium tuberculosis, the bacteria responsible for tuberculosis. It is a key component in the development of treatment plans for patients diagnosed with the condition.
Used in Drug Interaction Management:
3-HYDROXYBUTANOHYDRAZIDE is used with caution due to its potential for adverse effects such as hepatotoxicity and peripheral neuropathy, as well as its ability to interact with other medications. This necessitates close monitoring of patients during treatment to ensure safety and efficacy.
Used in Patient Monitoring:
3-HYDROXYBUTANOHYDRAZIDE is used in conjunction with regular health assessments to manage potential side effects and drug interactions, ensuring that patients receive the necessary care and support throughout their treatment for tuberculosis.

InChI:InChI=1/C4H10N2O2/c1-3(7)2-4(8)6-5/h3,7H,2,5H2,1H3,(H,6,8)

Upstream product

• 3068-88-0 4-methyloxetan-2-one 
• 1487-49-6 3-hydroxybutyric acid methyl ester 
• 5405-41-4 ethyl 3-hydroxybutyrate 

Downstream Products

• 678555-15-2 3-Hydroxy-butyric acid [1-(2-chloro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 133661-87-7 3-Hydroxy-butyric acid [1-(2-chloro-phenyl)-eth-(E)-ylidene]-hydrazide 

Relevant academic research and scientific papers

Discovery of a flexible triazolylbutanoic acid as a highly potent uric acid transporter 1 (URAT1) inhibitor

In order to systematically explore and understand the structure-activity relationship (SAR) of a lesinurad-based hit (1c) derived from the replacement of the S atom in lesinurad with CH2, 18 compounds (1a-1r) were designed, synthesized and subjected to in vitro URAT1 inhibitory assay. The SAR exploration led to the discovery of a highly potent flexible URAT1 inhibitor, 1q, which was 31-fold more potent than parent lesinurad (IC50 = 0.23 μM against human URAT1 for 1q vs. 7.18 μM for lesinurad). The present study discovered a flexible molecular scaffold, as represented by 1q, which might serve as a promising prototype scaffold for further development of potent URAT1 inhibitors, and also demonstrated that the S atom in lesinurad was not indispensable for its URAT1 inhibitory activity.

HETEROBICYCLO-SUBSTITUTED-7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER

Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.